6th September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.
To see the slides accompanying the presentation made at the AGM please click here.
1 September 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the appointment of Dr Claudia D’Augusta as a Non-executive Director of the Company, effective from the date of the Company’s Annual General Meeting on 6 September 2017. She will also chair the Company’s Audit Committee.
01 September 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
7 August 2017: ReNeuron Group plc (“the Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2017 and the Notice of the 2017 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.
The Annual Report and Accounts can be found under the Investors section or by clicking here.
25 July 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Nplus1 Singer Advisory LLP as joint broker to the Company with immediate effect.
19 July 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that Dr Paul Harper, a non-executive director of the business since the Company’s flotation on AIM in 2005, will step down from the Board at the next Annual General Meeting of the Company.
29 June 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2017.
To view the webcast of the 2017 preliminary results presentation click here..
19 June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on its cell therapy development programmes targeting degenerative diseases of the retina.
8th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2017 on Thursday 29 June 2017.
5th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a further update regarding its US clinical and regulatory development strategy for its CTX cell therapy candidate for stroke disability.
